fda warning letters glp-1 compounders october 2025 target marketers of unapproved weight loss drugs The growing availability of compounded

The team discusses how in sports nutrition, Setria is valued for extending pumps, while Cognizin serves different purposes, though the interplay between them is intriguing

CoQ10 helps reduce heart problems and keep your heart in top shape

If you are curious about the answers to these questions, keep reading

This triple-agonist approach, targeting GLP-1, GIP, and glucagon receptors, produced the most dramatic weight loss results seen in any Phase 2 obesity trial

Heres where they stand out: 99+% Pure Peptides: They publish Certificates of Analysis on all their peptide products to prove that they ship pure, research-grade peptides

Foundayo (orforglipron) received FDA approval in April 2026, and oral Wegovy tablets received FDA-approval in December 2025